脓毒症免疫抑制机制及治疗策略  

Mechanisms of immune suppression in sepsis and therapeutic strategies

作　　者：权震 温良鹤[1] 郑俊波[1] 王洪亮[1] Quan Zhen;Wen Lianghe;Zheng Junbo;Wang Hongliang(Department of Critical Care Medicine,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院重症医学科,黑龙江哈尔滨150086

出　　处：《中国急救医学》2024年第1期25-29,共5页Chinese Journal of Critical Care Medicine

基　　金：国家重点研发计划项目(2021YFC2501800);黑龙江省自然科学基金杰出青年项目(JQ2021H002)。

摘　　要：脓毒症是机体对感染反应失调引起的危及生命的器官功能障碍。随着研究的深入,对脓毒症的理解已经从单纯的炎症反应拓展到涉及免疫抑制和免疫失衡。本文综述了脓毒症免疫抑制的生物学机制和临床影响,评估了针对脓毒症免疫抑制的多种潜在治疗策略,包括免疫检查点抑制剂、免疫刺激性细胞因子、免疫球蛋白、胸腺素α1和间充质干细胞等。旨在为临床医生和研究者提供关于脓毒症免疫抑制的最新见解,并探索改善患者长期预后的新兴治疗方法。Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.As research has progressed,the understanding of sepsis has evolved from a mere inflammatory response to encompassing immune suppression and dysregulation.This review summarizes the biological mechanisms and clinical implications of immune suppression in sepsis,and evaluates various potential therapeutic strategies targeting this condition,including immune checkpoint inhibitors,immunostimulatory cytokines,immunoglobulins,thymosin alpha-1,and mesenchymal stem cells.The aim is to provide clinicians and researchers with up-to-date insights into immune suppression in sepsis and to explore emerging treatment methods to improve long-term outcomes of the patients.

关 键 词：脓毒症 免疫抑制 免疫治疗 免疫调控 免疫球蛋白 免疫刺激性细胞因子 胸腺素Α1 间充质干细胞 

分 类 号：R459.7[医药卫生—急诊医学]